Crinetics Pharmaceuticals, Inc.
- CRNX
- NASDAQ
- Biotechnology
- Endocrine Disease Therapeutics
- Rare Disease (Endocrine)
- Oral Peptide Drugs
$84.95
Quote Sep 1, 2026, 01:30 PM UTC
+1.30%over the last month
Max drawdown −0.1%From 1-month high 0.0%3 months +156.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist.
Where the money comes from
Q2 2026 revenue $25.1M
- Product$24.0M95.7%
- License and Service$1.1M4.3%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
594
Founded
2008
Market value
$9.01B
Quote Sep 1
Floor
$84.14
0.9% below price
Resistance
$85.04
0.1% above price
Price vs analyst targets
21 analysts
Lowest target
$84.00Highest target
$85.00
$84.00Highest target
$85.00
- Price $84.95
- Average target $84.86
- Analysts' target range
The price is close to the highest analyst target. Analysts' average target sits about 0% lower.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CRNXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free